Abstract
A mammalian model has been developed for the in vivo evaluation of bone imaging agents. The model is based upon the quantification of a discrete, initial secondary periosteal osteogenesis induced in cortical bone immediately adjacent to an intramuscularly implanted Walker 256 tumor in Fisher 344 rats. Evaluation of the model consists of a histopathological examination of the periosteal bone formation, biodistribution studies on 99 m Tc-MDP and 99 m Tc-HMDP commercial kit preparations, and biodistribution studies on two 99 m Tc-HEDP component fractions isolated after anion exchange chromatographic separations from an investigative “carrier added” preparation. Reversed phase HPLC separations of the 99 m Tc-MDP and 99 m Tc-HMDP commercial kit preparations illustrate distinct differences in chemical composition between the two bone agents.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Nuclear Medicine and Biology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
